Biotech's Boom Suffers a Setback in March April 01, 2014 | Press Release
Investors Flock to Biotech March 03, 2014 | Press Release
Biotech IPOs Off to a Strong Start in 2014 February 03, 2014 | Press ReleaseSee all News
FDA Commissioner Dr. Margaret Hamburg headlines at the Burrill Annual Personalized Medicine MeetingSeptember 16, 2009
SAN FRANCISCO - Newly confirmed FDA Commissioner Dr. Margaret Hamburg has vowed to enhance the FDA’s focus toward improving public health and at The Burrill Personalized Medicine Meeting, November 9-10 in San Francisco. Hamburg will provide attendees with the latest perspectives on regulatory policies and government initiatives that will help shape the adoption and impact of personalized medicine on healthcare.
However, in order for personalized medicine to be fully adopted into clinical practice it will require changes in regulation, and legislative protections for privacy. Governments will need to play a bigger role in funding and coordinating research while also eliminating regulatory hurdles that currently hinder the creation and adoption of innovative products and medical treatments.
Also on the first day Dr. George Poste, Chief Scientist, Complex Adaptive Systems Initiative at Arizona State University will present a second keynote entitled: “Health Technology Acceleration and Convergence,” where he will discuss the emergence of a new healthcare ecosystem based on increasingly comprehensive profiling of disease risk and health status.
“We are starting to see personalization of therapy become not just more widespread, but a best practice and a standard of care in certain disease areas. The pace of that trend will only increase as more and more targeted treatments reach the marketplace,” said G. Steven Burrill, CEO, Burrill & Company and organizer of the meeting.
Further details on the agenda may be obtained from: http://www.burrillandco.com/personalized_medicine_2009/